CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients

Pharmacogenomics

Volumn 18, Issue 4, 2017, Pages 337-348

  Balyan, Rajiv ^a   Mecoli, Marc ^a,b   Venkatasubramanian, Raja ^a   Chidambaran, Vidya ^a,b   Kamos, Nichole ^b   Clay, Smokey ^a,b   Moore, David L ^a,b   Mavi, Jagroop ^a,b   Glover, Chris D ^c   Szmuk, Peter ^d,e   Vinks, Alexander ^a,b   Sadhasivam, Senthilkumar ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e OUTCOMES RESEARCH CONSORTIUM   (United States)

Author keywords

CYP2D6; oxycodone; pediatrics; pharmacogenetics; pharmacokinetics; surgical pain

Indexed keywords

CYTOCHROME P450 2D6; OXYCODONE; OXYMORPHONE; NARCOTIC ANALGESIC AGENT;

ADOLESCENT; ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CYP2D6 GENE; DRUG BLOOD LEVEL; DRUG HALF LIFE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; OBSERVATIONAL STUDY; PEDIATRIC SURGERY; PHARMACOGENETICS; PILOT STUDY; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; CLINICAL TRIAL; FEMALE; GENETICS; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PAIN, POSTOPERATIVE; PHASE 4 CLINICAL TRIAL; PROCEDURES;

ADMINISTRATION, ORAL; ADOLESCENT; ANALGESICS, OPIOID; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; MALE; OXYCODONE; PAIN, POSTOPERATIVE; PHARMACOGENETICS; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 85014342998     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs-2016-0183     Document Type: Article

References (37)

1. Shum S, Lim J, Page T et al. An audit of pain management following pediatric day surgery at British Columbia Children's Hospital. Pain Res. Manag. 17(5), 328-334 (2012).
2. Stewart DW, Ragg PG, Sheppard S, Chalkiadis GA. The severity and duration of postoperative pain and analgesia requirements in children after tonsillectomy, orchidopexy, or inguinal hernia repair. Paediatr. Anaesth. 22(2), 136-143 (2012).
3. Bell GC, Donovan KA, Mcleod HL. Clinical implications of opioid pharmacogenomics in patients with cancer. Cancer Control 22(4), 426-432 (2015).
4. Niesters M, Overdyk F, Smith T, Aarts L, Dahan A. Opioidinduced respiratory depression in paediatrics: a review of case reports. Br. J. Anaesth. 110(2), 175-182 (2013).
5. Ewah BN, Robb PJ, Raw M. Postoperative pain, nausea and vomiting following paediatric day-case tonsillectomy. Anaesthesia 61(2), 116-122 (2006).
6. Gasche Y, Daali Y, Fathi M et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 351(27), 2827-2831 (2004).
7. Madadi P, Koren G. Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics 9(9), 1267-1284 (2008).
8. Saarenmaa E, Neuvonen PJ, Fellman V. Gestational age and birth weight effects on plasma clearance of fentanyl in newborn infants. J. Pediatr. 136(6), 767-770 (2000).
9. Tobias JD, Green TP, Cote CJ; Section on Anesthesiology and Pain Medicine; Committee on Drugs. Codeine: time to say 'no'. Pediatrics 138(4) pii: e201623966 (2006).
10. Koska AJ, 3rd, Romagnoli A, Kramer WG. Effect of cardiopulmonary bypass on fentanyl distribution and elimination. Clin. Pharmacol. Ther. 29(1), 100-105 (1981).
11. Coluzzi F, Mattia C. Oxycodone. Pharmacological profile and clinical data in chronic pain management. Minerva Anestesiol. 71(7-8), 451-460 (2005).
12. Marsousi N, Daali Y, Rudaz S et al. Prediction of metabolic interactions with oxycodone via CYP2D6 and CYP3A inhibition using a physiologically based pharmacokinetic model. CPT Pharmacometrics Syst. Pharmacol. 3, e152 (2014).
13. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin. Pharmacol. Ther. 79(5), 461-479 (2006).
14. Kokki M, Valitalo P, Rasanen I et al. Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. Eur. J. Clin. Pharmacol. 68(10), 1357-1363 (2012).
15. Linares OA, Daly D, Stefanovski D, Boston RC. The CYP2D6 gene determines oxycodone's phenotype-specific addictive potential: implications for addiction prevention and treatment. Med. Hypotheses 82(3), 390-394 (2014).
16. Samer CF, Daali Y, Wagner M et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br. J. Pharmacol. 160(4), 919-930 (2010).
17. Lam J, Kelly L, Ciszkowski C et al. Central nervous system depression of neonates breastfed by mothers receiving oxycodone for postpartum analgesia. J. Pediatr. 160(1), 33.e2-37.e2 (2012).
18. Samer CF, Piguet V, Dayer P, Desmeules JA. [Genetic polymorphism and drug interactions: their importance in the treatment of pain]. Can. J. Anaesth. 52(8), 806-821 (2005) (In French).
19. De Leon J, Dinsmore L, Wedlund P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J. Clin. Psychopharmacol. 23(4), 420-421 (2003).
20. Susce MT, Murray-Carmichael E, De Leon J. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog. Neuropsychopharmacol. Biol. Psychiatry 30(7), 1356-1358 (2006).
21. Samer CF, Daali Y, Wagner M et al. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br. J. Pharmacol. 160(4), 907-918 (2010).
22. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin. Pharmacol. Ther. 83(4), 559-566 (2008).
23. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCRbased detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 392(1), 30-34 (1996).
24. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83(2), 234-242 (2008).
25. Sakuyama K, Sasaki T, Ujiie S et al. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab. Dispos. 36(12), 2460-2467 (2008).
26. Fukuda T, Nishida Y, Imaoka S et al. The decreased in vivo clearance of CYP2D6 substrates by CYP2D610 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch. Biochem. Biophys. 380(2), 303-308 (2000).
27. Branford R, Droney J, Ross JR. Opioid genetics: the key to personalized pain control? Clin. Genet. 82(4), 301-310 (2012).
28. Cohen M, Sadhasivam S, Vinks AA. Pharmacogenetics in perioperative medicine. Curr. Opin. Anaesthesiol. 25(4), 419-427 (2012).
29. Eissing T, Lippert J, Willmann S. Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition. Mol. Diagn. Ther. 16(1), 43-53 (2012).
30. Sadhasivam S, Myer CM, 3rd. Preventing opioid-related deaths in children undergoing surgery. Pain Med. 13(7), 982-983; Author Reply 984 (2012).
31. Chang KL, Weitzel K, Schmidt S. Pharmacogenetics: using genetic information to guide drug therapy. Am. Fam. Physician 92(7), 588-594 (2015).
32. McLellan RA, Oscarson M, Seidegard J, Evans DA, Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 7(3), 187-191 (1997).
33. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 278(1), 441-446 (1996).
34. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet. 45(9), 931-956 (2006).
35. Andreassen TN, Eftedal I, Klepstad P et al. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. Eur. J. Clin. Pharmacol. 68(1), 55-64 (2012).
36. Zwisler ST, Enggaard TP, Noehr-Jensen L et al. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin. Pharmacol. Toxicol. 104(4), 335-344 (2009).
37. Crews KR, Gaedigk A, Dunnenberger HM et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin. Pharmacol. Ther. 95(4), 376-382 (2014).